Abstract
Background
This study aimed to describe the characteristics of patients diagnosed with hepatocellular carcinoma (HCC) at the Komfo Anokye Teaching Hospital (KATH) in Ghana and to determine their treatment options per the Barcelona Clinic Liver Cancer (BCLC) algorithm.
Methods
We reviewed the medical records of patients diagnosed with HCC at KATH in the period 2007–2013. Patient demographics, medical history, investigations, management, and outcome were extracted. BCLC staging was applied to determine their treatment options. Results were expressed as descriptive statistics.
Results
The charts for 206/465 patients were available for review. The male:female ratio was 2:1 and mean age was 44.0 ± 14.5 years. Common presenting complaints were abdominal distension, abdominal pain, and jaundice. hepatitis B virus (HBV) positivity was 52 %. Almost all patients received only supportive treatment. None underwent surgery, ablation, or transarterial chemoembolization. BCLC staging could be completed for 118 patients. Using predicted INR values in cases without the result, < 8 % of patients were eligible for resection, transplantation, or ablation; 25–53 % were eligible for embolization or sorafenib therapy. Up to 72 % were eligible only for supportive care. Seventy-six percent of patients reviewed were discharged alive; 71 % of patients whose charts were not available died during an admission. Thus, of the 465-patient cohort, 50 % died in the hospital.
Conclusions
The majority of HCC in our population is caused by HBV. Up to 61 % of patients may be eligible for curative treatment, transarterial chemoembolization, or sorafenib treatment. This percentage may be increased with a robust surveillance program for patients at increased risk for HCC. Hepatitis B vaccination must also be a public health priority.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917
Paul SB, Chalamalasetty SB, Vishnubhatla S et al (2009) Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India. Oncology 77(3–4):162–171
Elbatea H, Enaba M, Elkassas G et al (2011) Indications and outcome of colonoscopy in the middle of Nile delta of Egypt. Dig Dis Sci 56(7):2120–2123
Viviani S, Carrieri P, Bah E et al (2008) 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev 17(11):3216–3223
Seleye-Fubara D, Jebbin N (2007) Hepatocellular carcinoma in port Harcourt, Nigeria: clinicopathologic study of 75 cases. Ann Afr Med 6(2):54–57
Umoh NJ, Lesi OA, Mendy M et al (2011) Aetiological differences in demographical, clinical and pathological characteristics of hepatocellular carcinoma in the Gambia. Liver Int 31(2):215–221
Wiredu EK, Armah HB (2006) Cancer mortality patterns in Ghana: a 10-year review of autopsies and hospital mortality. BMC Public Health 6:159–165
Parkin DM, Sitas F, Chirenje M et al (2008) Part I: cancer in indigenous Africans-burden, distribution, and trends. Lancet Oncol 9(7):683–692
Sorensen JB, Klee M, Palshof T et al (1993) Performance status assessment in cancer patients. an inter-observer variability study. Br J Cancer 67(4):773–775
Bruix J, Sherman M, American Association for the Study of Liver Diseases (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022
Blankson A, Wiredu E, Gyasi R et al (2005) Seroprevalence of hepatitis B and C viruses in cirrhosis of the liver in Accra, Ghana. Ghana Med J 39(4):132–137
El-Serag HB (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142(6):1264–1273 e1261
Bosch FX, Ribes J, Diaz M et al (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1):S5–S16
Anthony PP (1973) Primary carcinoma of the liver: a study of 282 cases in Ugandan Africans. J Pathol 110(1):37–48
Kew MC (1989) Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology 97(1):136–139
Connock M, Round J, Bayliss S et al (2010) Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess 14(Suppl 1):17–21
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74–108
Disclosures
Drs. Gyedu, Shrauner, and Kingham have no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gyedu, A., Shrauner, W.R. & Kingham, T.P. No Patients to Resect or Transplant: An Analysis of Patients with Hepatocellular Carcinoma Admitted to a Major African Referral Hospital. World J Surg 39, 231–236 (2015). https://doi.org/10.1007/s00268-014-2762-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-014-2762-1